Hefei Linxinborui Biotechnology

Hefei Linxinborui Biotechnology is a specialized biotechnology company focused on the research and development of boron-containing pharmaceuticals for Boron Neutron Capture Therapy (BNCT). Headquartered in Hefei, China, the company originates from the technological incubation of the Hefei Institutes of Physical Science, Chinese Academy of Sciences. Their core business involves designing and synthesizing high-efficiency boron carriers that can selectively accumulate in tumor tissues to enable precise radiotherapy. Linxinborui's pipeline primarily targets difficult-to-treat malignancies, including glioblastoma and head and neck cancers. By integrating nuclear medicine with innovative drug delivery, the company seeks to establish a leading position in the emerging BNCT clinical landscape in Asia. The company is currently advancing its lead candidate, LX-001, through the preclinical stages required for regulatory submission.